H. Lundbeck A/S | Income Statement

Fiscal year is January-December. All values DKK Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
15,258
13,468
14,464
15,620
17,234
18,117
Cost of Goods Sold (COGS) incl. D&A
4,073
4,406
5,200
4,167
4,040
3,637
Gross Income
11,185
9,062
9,264
11,453
13,194
14,480
SG&A Expense
9,204
8,654
10,550
8,964
9,019
9,135
EBIT
1,981
408
1,286
2,489
4,175
5,345
Unusual Expense
947
308
5,660
211
10
92
Non Operating Income/Expense
504
65
55
52
208
16
Interest Expense
82
105
124
79
108
-
Pretax Income
1,472
56
7,006
2,157
4,277
5,289
Income Tax
617
97
1,312
946
1,653
1,382
Consolidated Net Income
855
153
5,694
1,211
2,624
3,907
Net Income
855
153
5,694
1,211
2,624
3,907
Net Income After Extraordinaries
855
153
5,694
1,211
2,624
3,907
Net Income Available to Common
855
153
5,694
1,211
2,624
3,907
EPS (Basic)
4.36
0.78
28.98
6.14
13.29
19.67
Basic Shares Outstanding
196
196
196
197
198
199
EPS (Diluted)
4.36
0.78
28.95
6.13
13.27
19.66
Diluted Shares Outstanding
196
196
197
197
198
199
EBITDA
2,995
1,639
80
3,832
5,424
6,528
Non-Operating Interest Income
16
14
9
10
12
52

About H. Lundbeck A/S

View Profile
Address
Ottiliavej 9
Valby CR 2500
Denmark
Employees -
Website http://www.lundbeck.com
Updated 07/08/2019
H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets.